PainChek Ltd.

PainChek Ltd. develops PainChek®, a clinically validated AI-enabled digital medical device for pain assessment in aged care, home care, hospitals, and neonatal settings. The software uses AI-driven technology and visual assessment to identify pain in individuals who cannot reliably self-report, including those with moderate to severe dementia. PainChek® generates personalized pain profiles and delivers results in under three minutes. The platform integrates seamlessly with leading Care Management Systems (CMS) and includes PainChek® Analytics, a cloud-based data intelligence portal providing actionable insights on pain trends and clinical outcomes. The company has facilitated over 15.9 million clinical assessments across 1,900+ facilities worldwide. PainChek® holds FDA De Novo clearance in the United States, is TGA-registered in Australia, and is approved for use in New Zealand, Canada, Singapore, Malaysia, the United Kingdom, and the European Union. Clinical evidence demonstrates reduced inappropriate use of psychotropic medications, increased pain assessments in cognitively impaired residents, and improved quality of life. The application is available on iOS and Android platforms. PainChek® supports care facilities in digital transformation while maintaining compliance with regulatory standards across multiple jurisdictions.